sur Gimv (EBR:GIMB)
Spineart Secures CHF 25 Million to Boost Global Growth
Gimv and EGS Beteiligungen have announced a CHF 25 million capital injection to Spineart, a medtech firm specializing in advanced spine surgery solutions, to support its global expansion. This funding aims to foster Spineart's innovation pipeline and enhance its worldwide presence, improving outcomes for spine surgery patients.
Spineart is known for its cutting-edge technologies that make spine surgeries safer and more effective. The company is expanding across Europe and the US, with ongoing FDA submissions for its BAGUERA® C cervical disc prosthesis. With strategic investments in digital navigation and robotics, Spineart is positioned to grow further.
With 360 professionals globally and projected 2025 revenues of EUR 140 million, Spineart has been experiencing consistent growth. The new investment marks a pivotal point in its expansion strategy, aligning with its goals of delivering innovative spine solutions globally.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Gimv